Table 4.

Bleeding control by treated site

Treated Site (N)	Change in grade	Baseline to End of RT n (%)	Baseline to End of follow-up n (%)	End of RT to End of follow-up n (%)
Uterovaginal (N=19)	Worsened	-	1 (5.3%)	2 (10.5%)
	No change	1 (5.3%)	1 (5.3%)	10 (52.6%)
	Improved	18 (94.7%)	15 (78.9%)	5 (26.3%)
	Missing	-	2 (10.5%)	2 (10.5%)
Bladder (N=17)	Worsened	-	2 (11.8%)	5 (29.4%)
	No change	6 (35.3%)	4 (23.5%)	8 (47.1%)
	Improved	11 (64.7%)	10 (58.8%)	3 (17.6%)
	Missing	-	1 (5.9%)	1 (5.9%)
Lung (N=10)	Worsened	-	-	-
	No change	-	-	6 (60.0%)
	Improved	10 (100.0%)	8 (80.0%)	2 (20.0%)
	Missing	-	2 (20.0%)	2 (20.0%)
Upper GI (N=10)	Worsened	1 (10.0%)	3 (30.0%)	2 (20.0%)
	No change	-	-	4 (40.0%)
	Improved	9 (90.0%)	6 (60.0%)	3 (30.0%)
	Missing	-	1 (10.0%)	1 (10.0%)
Other (N=6)*	Worsened	-	-	-
	No change	-	-	5 (83.3%)
	Improved	6 (100.0%)	6 (100.0%)	1 (16.7%)

Abbreviations: ^*including lower gastrointestinal (n=4), skin (n=1) and abdominal wall (n=1).